GYNECOMASTIA DURING THERAPY WITH NILOTINIB (AMN 107) FOR CHRONIC MYELOID LEUKEMIA – A RARE CASE REPORT.
*Lalit Prashant Meena, Jaya Chakravarty, Saurabh Chopra, Siddharth Samrat, Madhukar Rai
Nilotinib (AMN107) exhibits superior potency to imatinib as an inhibitor of wild-type BCR-ABL in a wide range of CML-derived and transfected cell lines. gynecomastia in male patients treated with imatinib and dasatinib has been reported in few cases.But gyenecomastia due to Nilotinib is never reported.Here we report the first case of Nilotinib induced gyenecomastia. 40 years old male patient was diagnosed as CML with chronic phase . Initially for two years he took Imatinib mesylate, but later on he was shifted on Nilotinib due to development of resistant to Imatinib. After six to seven month of treatment with nilotinib, he developed gynecomastia.
[Full Text Article]